PubMed HealthSearch

Biomedical subjects

C Engelhard

Publications and source records attributed to C Engelhard.

3 recordsLinked to original sources

Weekly psoriasis therapy using intralesional fluorouracil.

We report the use of weekly intralesional fluorouracil for treatment of entire psoriatic papules and portions of larger psoriatic plaques. Eleven patients participated and responded, with an average of 4.2 cm2 clearing about the injection site in the treated lesions, in comparison with no improvement in the control lesions. We injected 1 ml of fluorouracil (50 mg/ml) to form an intradermal wheal of about 0.8 cm2. Each patient received one to three injections at 1- to 2-week intervals, with an average of two injections per patient. The earliest signs of improvement occurred at 2 weeks; maximum clearing was achieved usually about 4 weeks after treatment began. At 3-month follow-up, four of the nine patients who had favorable response to treatment remained substantially in remission. Toxic effects were limited to local hyperpigmentation in seven patients, slight irritation in two patients, and moderate irritation in one patient. No systemic toxic effects were shown. Weekly pulse doses of fluorouracil given intralesionally instead of topically can greatly speed up response to therapy and can produce similarly good results. Intralesional administration of fluorouracil is locally effective, is often of long-term benefit, and can be tolerated well.

Administration, Topical

Weekly pulse dosing schedule of fluorouracil: a new topical therapy for psoriasis.

We report use of a new weekly pulse dosing schedule of 5% fluorouracil under occlusion for topical treatment of recalcitrant psoriasis. This schedule eliminates the severe local toxicity reported in continuous dosing schedules. The thirteen outpatients completing this study were given continuous topical application of fluorouracil for a mean of 2 to 3 days per week; mean duration of therapy was 15.7 weeks. Eleven patients had an average of 90% clearing of actively treated lesions; 6% clearing was obtained with placebo. At 3-month follow-up examination, improvement was maintained in five patients, was maintained by at least 50% in two, and was lost in four. The five patients with remission at 3 months reported continued remission for up to an additional 8 months. This pulse dosing schedule makes topical fluorouracil under occlusion a useful, safe treatment for limited plaque psoriasis that does not respond to topical corticosteroid therapy.

Administration, Topical